Identification | Back Directory | [Name]
N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine | [CAS]
477600-74-1 | [Synonyms]
TF-G Tofacitinib-11 Tofacitinib IMpurity M tofacitinib intermediate Tofacitinib N-Descyanoacetyl H-Pyrrolo[2,3-d]pyriMidin-4-aMine Tofacitinib N-Descyanoacetyl Impurity N-Methyl-N-[(3R,4R)-4-Methylpiperidin-3-yl]-7H-pyrrolo[2,3-d] (3R,4R)-N,4-diMethyl-N-{7H-pyrrolo[2,3-d]pyriMidin-4-yl}piperidin-3-aMine N-Methyl-N-[(3R,4R)-4-methyl-3-piperidyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amin N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-1H-pyrrolo[2,3-d]pyrimidin-4-amine N-methyl-N-((3S,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (3R,4R)-Methyl{(4-Methylpiperidin-3-yl)(7H-pyrrolo[2,3-d]pyriMidin-4-yl)}aMine 7H-Pyrrolo[2,3-d]pyriMidin-4-aMine, N-Methyl-N-[(3R,4R)-4-Methyl-3-piperidinyl]- 1H-Pyrrolo[2,3-d]pyriMidin-4-aMine,N-Methyl-N-[(3R,4R)-4-Methyl-3-piperidinyl]- (9CI) N-Methyl-N-((3R,4R)-4-Methyl-piperidin-3-yl)-N-Methyl-7H-pyrrolo[2,3-d]pyriMidin-4-aMine N-METHYL-N-((3R,4R)-4-METHYLPIPERIDIN-3-YL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-AMINE (CAS NO.477600-74-1) Tofacitinib impurity 7/N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine N-Methyl-N-((3R,4R)-4-Methylpiperidin-3-yl)-7HMethylpiperidin-3-yl)-7Hpyrrolo[
2,3-d]pyriMidin-4-aMine | [Molecular Formula]
C13H19N5 | [MDL Number]
MFCD09878608 | [MOL File]
477600-74-1.mol | [Molecular Weight]
245.323 |
Chemical Properties | Back Directory | [Melting point ]
157 - 162°C | [density ]
1?+-.0.06 g/cm3(Predicted) | [storage temp. ]
Keep in dark place,Sealed in dry,2-8°C | [solubility ]
Aqueous Acid (Slightly), Methanol (Slightly), Water (Slightly, Heated) | [form ]
Solid | [pka]
13.36±0.50(Predicted) | [color ]
White to Off-White | [InChI]
InChI=1S/C13H19N5/c1-9-3-5-14-7-11(9)18(2)13-10-4-6-15-12(10)16-8-17-13/h4,6,8-9,11,14H,3,5,7H2,1-2H3,(H,15,16,17)/t9-,11+/m1/s1 | [InChIKey]
XRIARWQZLGCQDM-KOLCDFICSA-N | [SMILES]
C1=NC(N(C)[C@@H]2[C@H](C)CCNC2)=C2C=CNC2=N1 |
Hazard Information | Back Directory | [Description]
N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine(477600-74-1) is an important pharmaceutical intermediate that is a by-product of the preparation of tofacitinib. Tofacitinib belongs to a class of Janus kinase (JAK) inhibitors used in the treatment of rheumatoid arthritis and psoriatic arthritis.
| [Uses]
N-Methyl-N-((3S,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine(477600-74-1), is an intermediate in the synthesis of (3S,4R)-Tofacitinib (T528010), an enantiopure stereoisomer of the drug, Janus kinase 3(Jak3) inhibitor (CP-690,550) that has been found to inhibit selected members of the STE7 and STE20 subfamily of kinases.
|
|
|